Back to Agenda
Safety Issues in First-in-Human Studies
Session Chair(s)
David Jones, MS
Consultant, Regulatory Pharmaco-Toxicologist, ApconiX, United Kingdom
The session deals with overcoming or assessing safety concerns and issues early in development and exploring some of the safety issues that you can address in early clinical trials with a focus on biomarkers. It showcases where preclinical and clinical meet demonstrating a variety of organ markers. Examples of different organ systems impacted or assessed may include use of markers in renal toxicity, testicular safety or cardiac assessments as examples.
Learning Objective : Identify methods that are useful to address early safety issues in FIH studies which is originally seen in toxicity data.
Speaker(s)
David Jones, MS
Consultant, Regulatory Pharmaco-Toxicologist, ApconiX, United Kingdom
The New EU Guidance for First-In-Human Clinical Trials
Charu Gautam, MD
Senior Director- Medical Science and Strategy, IQVIA, India
Safety Issues in First-in-Human Studies
Paul Baldrick, PHD
, Covance Inc., United Kingdom
First-In-Human Nonclinical Testing and Starting Dose Considerations
Have an account?